Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.

Vasey, P A; Shulman, L N; Campos, S; Davis, J; Gore, M; Johnston, S; Kirn, D H; O'Neill, V; Siddiqui, N; Seiden, M V; Kaye, S B

Vasey, P A; Shulman, L N; Campos, S; Davis, J; Gore, M; Johnston, S; Kirn, D H; O'Neill, V; Siddiqui, N; Seiden, M V; Kaye, S B.

Affiliation

Vasey PA; Beatson Oncology Centre and Stobhill Hospital, Glasgow, United Kingdom. pav1y@clinmed.gla.ac.uk

J Clin Oncol ; 20(6): 1562-9, 2002 Mar 15.

Article in En | MEDLINE | ID: mdl-11896105

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Genetic Therapy / Adenovirus E1B Proteins Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: J Clin Oncol Year: 2002 Document type: Article Affiliation country: Country of publication:

Search on Google

Add to My VHL

XML

PubMed Links